Results of a new study show that patients guided to targeted therapy based on ctDNA get the same benefits as those who got tissue-based tests in initial clinical trials.
N-of-One will provide treatment strategies and clinical trial opportunities for patients based on Inivata's ctDNA liquid biopsy test.
Inivata has completed the analytical validation of its 35-gene ctDNA test and plans to conduct clinical validation studies from labs in North Carolina and the UK.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.